NATAP/EASL: 泰诺福韦HBV/肝癌风险

StephenW

> Subject: NATAP/EASL: Tenofovir HBV/HCC Risk
>
> Long-term Tenofovir Disoproxil Fumarate (TDF) Therapy and the Risk of Hepatocellular Carcinoma
>
>  - see attached full slide presentation
>

>
> Reported by Jules Levin
>
> EASL 2013 April 24-28 Amsterdam
>
>  
>
> W. Ray Kim1, Thomas Berg2, Rohit Loomba3, Raul Aguilar Schall4, Phillip Dinh4, Leland J. Yee4, Eduardo Bruno Martins4, John F. Flaherty4, Selim Gurel5, Maria Buti6, Patrick Marcellin7
>
> 1Mayo Clinic, Rochester, MN, USA; 2Universitätsklinikum Leipzig, Germany; 3University of California at San Diego, USA; 4Gilead Sciences, Inc., Foster City, CA; 5University of Uludag, Bursa, Turkey; 6Hospital General Universitari Vall d’Hebron, Barcelona, Spain; 7Hôpital Beaujon, University of Paris, Clichy, France
>
> HCC is an important complication of CHB1
> Risk score algorithms have been developed to estimate risk of developing HCC2‒5
> The impact of therapy with oral antivirals, such as TDF, on the development of HCC has not been
> well characterized
>
> STUDY AIM
> To compare the observed incidence of HCC in patients treated with TDF in studies GS-US-174-0102 and GS-US-174-0103 with the predicted HCC incidence based on the REACH-B risk calculator
>
> Author’s SUMMARY
>
> The incidence of HCC in patients on TDF in studies GS-US-174-0102 and GS-US-174-0103 was lower than predicted by the REACH-B model
> In noncirrhotic patients, the effect of TDF becomes noticeable at approximately 2 years of therapy and became significant (55% reduction) at 6 years of therapy
> TDF effect was less pronounced in cirrhotic patients; however, the number of cirrhotics with HCC was small and may not rule out longer-term benefits
>

StephenW

是肝癌的重要并发症之一CHB1
>风险评分算法已经被开发来估算风险的，开发HCC2-5
冲击疗法与口服抗病毒剂，如TDF，还没有得到关于肝癌的发展
>很好的特点
>
>研究目的
>预测肝癌的发生率，基于REACH-B的风险计算器TDF的研究GS-US-174-0102，GS-US-174-0103，对待患者的肝癌发病率比较观察
>
>作者的总结
>
患者对TDF的研究GS-US-174-0102，GS-US-174-0103肝癌的发病率低于预期通过REACH-B模型
在肝硬化的患者，TDF的效果变得显着的治疗约2年，并成为显着性（减少55％）在治疗6年
> TDF效果是不太明显的肝硬化患者，但是，肝硬化与肝癌的数量很小，可能不排除长期效益

StephenW

疯一点好

替诺无癌？那是非同一般好消息啊。

StephenW

疯一点好 发表于 2013-5-9 16:37
替诺无癌？那是非同一般好消息啊。

不是替诺无癌, 是减少.